Practice of adjunctive treatments in critically ill COVID-19 patients-rational for the multicenter observational PRoAcT-COVID study in The Netherlands

Autor: Lieuwe D. J. Bos, Christel M A Valk, Ward H. van der Ven, Sunny G Nijbroek, Guido Mazzinari, Anissa M. Tsonas, Leonoor S Boers, Sheila Nainan Myatra, Marcelo Gama de Abreu, Ary Serpa Neto, Willemke Stilma, Janneke Horn, Michela Botta, Markus W. Hollmann, Liselotte Hol, Neeltje M Rosenberg, Frederique Paulus, Pien Swart, Ignacio Martin-Loeches, Marcus J. Schultz
Přispěvatelé: Faculteit Gezondheid, Urban Vitality, Intensive Care Medicine, Graduate School, Anesthesiology, APH - Quality of Care, ACS - Heart failure & arrhythmias, Nursing, AII - Inflammatory diseases, ACS - Pulmonary hypertension & thrombosis, APH - Personalized Medicine, APH - Global Health, ACS - Microcirculation, ACS - Diabetes & metabolism
Rok vydání: 2021
Předmět:
Zdroj: Ann Transl Med
Annals of Translational Medicine, 9(9). AME Publishing Company
Annals of translational medicine
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Annals of translational medicine, 9(9). AME Publishing Company
ISSN: 2305-5839
0471-9182
Popis: Background: Patients with coronavirus disease 2019 (COVID-19) may need hospitalization for supplemental oxygen, and some need intensive care unit (ICU) admission for escalation of care. Practice of adjunctive and supportive treatments remain uncertain and may vary widely between countries, within countries between hospitals, and possibly even within ICUs. We aim to investigate practice of adjunctive and supportive treatments, and their associations with outcome, in critically ill COVID-19 patients.Methods: The 'PRactice of Adjunctive Treatments in Intensive Care Unit Patients with Coronavirus Disease 2019' (PRoAcT-COVID) study is a national, observational study to be undertaken in a large set of ICUs in The Netherlands. The PRoAcT-COVID includes consecutive ICU patients, admitted because of COVID-19 to one of the participating ICUs during a 3-month period. Daily follow-up lasts 28 days. The primary endpoint is a combination of adjunctive treatments, including types of oxygen support, ventilation, rescue therapies for hypoxemia refractory to supplementary oxygen or during invasive ventilation, other adjunctive and supportive treatments, and experimental therapies. We will also collect tracheostomy rate, duration of invasive ventilation and ventilator-free days and alive at day 28 (VFD-28), ICU and hospital length of stay, and the mortality rates in the ICU, hospital and at day 90.Discussion: The PRoAcT-COVID study is an observational study combining high density treatment data with relevant clinical outcomes. Information on treatment practices, and their associations with outcomes in COVID-19 patients in highly and urgently needed. The results of the PRoAcT-COVID study will be rapidly available, and circulated through online presentations, such as webinars and electronic conferences, and publications in peer-reviewed journals-findings will also be presented at a dedicated website. At request, and after agreement of the PRoAcT-COVID steering committee, source data will be made available through local, regional and national anonymized datasets.Trial registration: The PRoAcT-COVID study is registered at clinicaltrials.gov (study identifier NCT04719182).
Databáze: OpenAIRE